18 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jul 2038. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Jul 2038

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

202620272028202920302031203220332034203520362037203820392040 2041 2042204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Deuterated Compounds US 11,773,062

Cited by 23 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2041.

Ends Apr 2041 · High confidence Also notable

Synthesis of N,n-Dimethyltryptamine-Type Compounds, Methods, and Uses US 11,643,390

Cited by 34 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2040.

Ends Nov 2040 · High confidence Also notable

Injectable Formulations US 11,406,619

Cited by 29 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2040.

Ends Aug 2040 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 11, 2027
The maintenance fee for 5-Methoxy-N,N-DIMETHYLTRYPTAMINE Crystalline Forms (US 11,697,638) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
2 fees due Apr 3, 2027

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 5 largest of its 11 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Deuterated Compounds	3 in force	to Jun 2041
Synthesis of N,n-Dimethyltryptamine-Type Compounds, Methods, and Uses	3 in force	to Nov 2040
Deuterated or Partially Deuterated N,n-Dimethyltryptamine Compounds	2 in force	to Nov 2041
Compounds	2 in force	to Nov 2040
Injectable Formulations	2 in force	to Aug 2040

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 11,377,416	Crystalline Forms of Hydroxynorketamine In force Term ends Jul 31, 2038 · High confidence	In force	Term ends Jul 31, 2038	High confidence
US 11,771,681	Therapeutic Compounds In force Ends no later than Jun 2, 2040 · Medium confidence	In force	Ends no later than Jun 2, 2040	Medium confidence
US 12,076,311	Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,n-Dimethyltryptamine Compounds In force Term ends Jun 2, 2040 · Medium confidence	In force	Term ends Jun 2, 2040	Medium confidence
US 11,406,619	Injectable Formulations In force Term ends Aug 28, 2040 · High confidence	In force	Term ends Aug 28, 2040	High confidence
US 12,343,327	Injectable Formulations In force Term ends Aug 28, 2040 · High confidence	In force	Term ends Aug 28, 2040	High confidence
US 11,578,039	Compounds In force Ends no later than Nov 9, 2040 · Medium confidence	In force	Ends no later than Nov 9, 2040	Medium confidence
US 11,643,390	Synthesis of N,n-Dimethyltryptamine-Type Compounds, Methods, and Uses In force Term ends Nov 9, 2040 · High confidence	In force	Term ends Nov 9, 2040	High confidence
US 12,084,417	Synthesis of N,n-Dimethyltryptamine-Type Compounds, Methods, and Uses In force Term ends Nov 9, 2040 · High confidence	In force	Term ends Nov 9, 2040	High confidence
US 12,157,723	Compounds In force Ends no later than Nov 9, 2040 · Medium confidence	In force	Ends no later than Nov 9, 2040	Medium confidence
US 12,649,718	Synthesis of N,n-Dimethyltryptamine-Type Compounds, Methods, and Uses In force Term ends Nov 9, 2040 · Medium confidence	In force	Term ends Nov 9, 2040	Medium confidence

10 of 18 patents shown.

Pro members see all 18.

Pro members: see all 18 patents

Also on record, not counted in the 18: 11 applications pending · 5 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Cybin UK Ltd.